Analysis of blood and tissue samples by the Pastan laboratory identified elevated levels of soluble and surface bound FCRL5 in multiple myeloma, CLL, and mantle cell lymphoma patient samples (33). Here, FCRL5 is linked to plasma cell myeloma.